Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.vaccine.2021.10.074 http://scihub22266oqcxt.onion/10.1016/j.vaccine.2021.10.074 34802792!8580836!34802792     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccine 2021 ; 39 (51): 7367-7374 Nephropedia Template TP {{tp|p=34802792|t=2021. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity |pdf=|usr=}}{{34802792}} gab.com Text BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity JO: Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=34802792 #FOAvip We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naive individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naive HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines. Study Registration. The study was registered on clinicaltrials.gov, NCT04402827. Twit Text FOAVip BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity ????Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=34802792 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34802792 #FOAvip English Wikipedia <ref>{{Cite pmid|34802792}}</ref> BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity #MMPMID34802792 Vizcarra P; Haemmerle J; Velasco H; Velasco T; Fernandez-Escribano M; Vallejo A; Casado JL Vaccine 2021[Dec]; 39 (51): 7367-7374 PMID34802792show ga We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naive individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naive HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines. Study Registration. The study was registered on clinicaltrials.gov, NCT04402827. |*COVID-19[MESH] |*COVID-19 Vaccines[MESH] |BNT162 Vaccine[MESH] |Humans[MESH] |RNA, Messenger/genetics[MESH]BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunit(epmc).pdf DeepDyve Pubget Overpricing